Clinical partnerships in the medical cannabis industry are providing clinicians with the practical knowledge they need to make better-informed treatment decisions for their patients.

In more ways than one, the key to growth and expansion in the medical cannabis space is knowledge, and the pursuit of knowledge applies to all stakeholders in the cannabis industry. Patients are taking the time to learn more about how medical cannabis can provide them with new treatments that can help alleviate their symptoms and ailments. Physicians are performing their due diligence to learn the facts about these emerging cannabis treatments. Cannabis companies are learning more about consumer needs and tailoring their product offerings accordingly. Researchers are conducting the leg work that proves the efficacy and legitimacy of cannabis as a medicine. As everyone involved learns more, there is more opportunity for growth in the medical cannabis space.

The medical cannabis industry is growing at a strong and steady pace. According to data collected by Research and Markets, the global industry will be worth more than $37 billion by 2023, up from more than $11 billion in 2017 for a compound annual growth rate of 22 percent. Global Market Insights projects the US medical cannabis market could be worth more than $8 billion by 2024. In Canada, where the medical side of the cannabis industry is now part of a much larger space, medical cannabis alone is still expected to generate between $0.77 and $1.79 billion in sales by the end of 2019, according to Deloitte Canada’s 2018 Cannabis Report.


What you need to know about Tesla's Battery Day

Expert Analysis of Tesla's Battery Day and the impact on Battery Metals Investing.

The barriers to medical cannabis research are finally coming down, and, with a wave of legalization, the medical cannabis industry continues to spread throughout North America, into Europe and beyond. This movement has created more opportunities for researchers and medical institutions to form clinical research partnerships to better understand the needs of patients and the potential of medical cannabis to meet those needs.

Understanding medical cannabis

The therapeutic benefits of medical cannabis have been apparent for decades. However, cannabis spent nearly 100 years under strict prohibition that did little to keep the plant out of the hands of recreational users while significantly hindering our understanding of the drug. Over the past 20 years, medical cannabis research has made significant progress filling in the gaps of our scientific understanding of cannabis. However, there is still much to be learned about the best methods of use, the optimal combinations of cannabinoids and the other factors that govern the efficacy of medical cannabis.

This in itself is the reason why some selected medical cannabis companies are choosing to partner with research groups and academic institutions to conduct clinical trials aimed at developing and refining cannabis products.

Cannabis companies have also partnered with medical clinics that provide medical cannabis products to their patients. This strategy gives researchers and cannabis product developers insight into the needs and experiences of real cannabis patients. With a greater understanding of medical cannabis and the needs of patients, medical cannabis companies can tailor their products to better treat the specific ailments and preferences of those patients. Furthermore, with a higher volume of evidence-based trials and research to draw from, physicians will gain better insight and confidence in medical cannabis treatments, making them more likely to recommend and prescribe those treatments.

In addition to supporting overall research and development, these partnerships also offer strategic avenues for a company’s overall growth. Taking a key leadership role in the advancement of medical cannabis research better positions a cannabis company as a thought leader and innovator in the medical cannabis space, helping it build and solidify its brand reputation and commitment to the medical community.

Clinical partnerships in the medical cannabis industry

In September 2018, Canadian medical cannabis producer Pure Global Cannabis (TSXV:PURE,OTCMKTS:PRCNF,FWB:1QS) announced that, through its subsidiary PureSinse, the company had formed a clinical partnership with Appletree Medical Group. Together the companies will conduct an observational study to describe the effectiveness of medical cannabis strains and cannabinoid-terpene combinations used in real world clinical settings for a variety of medical conditions. The pan-Canadian study will be overseen by a global clinical research organization specialized in harnessing information and data analytics that drive healthcare forward.

The goal of the study is to provide Pure Global with key insights that will shape and inform the development of improved treatments for neuropathic pain, insomnia, anxiety disorders, opioid dependence, PTSD and more.

“Clinic partnerships are part of our mission to brand ourselves to the medical community as a trusted partner for the education and supply of medical cannabis products. We are conducting a real world, evidence-based study on the therapeutic effects of cannabis to give physicians and healthcare professionals the evidence and data they need to help patients choose the best cannabis treatment options,” Pure Global CEO Malay Panchal told the Investing News Network. “This in turn will give healthcare professionals, including physicians, pharmacists, nurses and naturopaths, the confidence to send their patients to PureSinse for their medical cannabis needs.”

Research partnerships like Pure Global and Appletree’s are becoming a more common practise in the medical cannabis industry. Canadian cannabis company Canntrust Holdings (TSX:TRST) announced in September 2018 that the company would be partnering with McMaster University in Hamilton, Ontario, as well as Hamilton Health Sciences’ Michael G. DeGroote Pain Clinic, to conduct clinical trials to research the therapeutic use and clinical effectiveness of cannabinoids. In August 2016, Canadian cannabis giant Aurora Cannabis (NYSE:ACB,TSX:ACB) announced that the company would be working with McGill University to launch an international collaborative medical research project on the therapeutic effects and health outcomes of cannabidiol therapy for chronic pain, anxiety and depression.


When more is understood about the effects and benefits of medical cannabis, everyone wins. Physicians are able to confidently prescribe cannabis as a game-changing alternative to opioids, cannabis producers see greater opportunity for growth in a thriving medical cannabis space and patients gain effective and safe treatment options. The full potential of medical cannabis remains unknown, but many companies are moving towards that potential by securing clinical partnerships.

This article was written according to INN editorial standards to educate investors.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less


Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less